79.93
price down icon0.15%   -0.12
after-market Dopo l'orario di chiusura: 79.75 -0.18 -0.23%
loading

Astrazeneca PLC Borsa (AZN) Ultime notizie

pulisher
Aug 27, 2025

University of Michigan Suit Targets AstraZeneca FluMist Profits - Bloomberg Law News

Aug 27, 2025
pulisher
Aug 27, 2025

AstraZeneca increasing focus on US market, as it is 'first to provide access to patients': CFO [Video] - AOL.com

Aug 27, 2025
pulisher
Aug 27, 2025

Global Pharmaceuticals Market to Register Immense Growth at a CAGR of ~7% by 2032 | DelveInsight - GlobeNewswire Inc.

Aug 27, 2025
pulisher
Aug 27, 2025

AstraZeneca and Icon Plc’s Study on ATTR Amyloidosis: Key Insights for Investors - TipRanks

Aug 27, 2025
pulisher
Aug 27, 2025

Published on: 2025-08-27 08:26:33 - Newser

Aug 27, 2025
pulisher
Aug 27, 2025

Va. backs big pharma deals for AstraZeneca in Albemarle, Eli Lilly in Goochland - Richmond Times-Dispatch

Aug 27, 2025
pulisher
Aug 27, 2025

Evaluating AstraZeneca PLC Depositary Receipt with trendline analysis2025 Big Picture & Accurate Entry and Exit Point Alerts - Newser

Aug 27, 2025
pulisher
Aug 27, 2025

Tools to monitor AstraZeneca PLC Depositary Receipt recovery probabilityWeekly Market Report & Weekly Top Gainers Alerts - Newser

Aug 27, 2025
pulisher
Aug 27, 2025

AstraZeneca bounces back from scandal in China - Financial Times

Aug 27, 2025
pulisher
Aug 26, 2025

AstraZeneca PLC Depositary Receipt Recovery Hinges on Volume Breakout getLinesFromResByArray error: size == 0 - 더경남뉴스

Aug 26, 2025
pulisher
Aug 26, 2025

AstraZeneca Sees Increase in Voting Rights by The Capital Group - TipRanks

Aug 26, 2025
pulisher
Aug 26, 2025

What candlestick patterns are forming on AstraZeneca PLC Depositary Receipt2025 Market Outlook & Daily Stock Trend Watchlist - Newser

Aug 26, 2025
pulisher
Aug 26, 2025

Published on: 2025-08-26 09:01:55 - Newser

Aug 26, 2025
pulisher
Aug 26, 2025

Is a relief rally coming for AstraZeneca PLC Depositary Receipt holdersWeekly Profit Analysis & Reliable Volume Spike Trade Alerts - Newser

Aug 26, 2025
pulisher
Aug 26, 2025

Multi asset correlation models including AstraZeneca PLC Depositary Receipt2025 Macro Impact & Breakout Confirmation Trade Signals - Newser

Aug 26, 2025
pulisher
Aug 25, 2025

AstraZeneca PLC ADR falls Monday, underperforms market - MarketWatch

Aug 25, 2025
pulisher
Aug 25, 2025

AstraZeneca’s New NSCLC Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Aug 25, 2025
pulisher
Aug 25, 2025

Daiichi Sankyo and AstraZeneca’s Datroway receives approval in China - Pharmaceutical Technology

Aug 25, 2025
pulisher
Aug 24, 2025

Is it time to cut losses on AstraZeneca PLC Depositary ReceiptPrice Action & Stock Market Timing Techniques - Newser

Aug 24, 2025
pulisher
Aug 24, 2025

AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica

Aug 24, 2025
pulisher
Aug 23, 2025

AstraZeneca’s New Asthma Study: Potential Market Impact - TipRanks

Aug 23, 2025
pulisher
Aug 22, 2025

AstraZeneca’s New Study on Tezepelumab for CRSwNP: A Potential Game-Changer - TipRanks

Aug 22, 2025
pulisher
Aug 22, 2025

Amgen and AstraZeneca Launch Promising Phase 3 Lung Cancer Study - TipRanks

Aug 22, 2025
pulisher
Aug 22, 2025

AstraZeneca’s Innovative Lung Cancer Screening Study: A Game Changer for Early Detection - TipRanks

Aug 22, 2025
pulisher
Aug 22, 2025

AstraZeneca’s ARISE Study: Real-World Insights on Acalabrutinib for CLL - TipRanks

Aug 22, 2025
pulisher
Aug 22, 2025

AstraZeneca’s DESTINY-Endometrial01 Study: A New Horizon in Endometrial Cancer Treatment - TipRanks

Aug 22, 2025
pulisher
Aug 22, 2025

AstraZeneca’s AZD9829 Study: A New Hope in Hematological Cancer Treatment - TipRanks

Aug 22, 2025
pulisher
Aug 21, 2025

AstraZeneca’s GEMINI-PeriOp GC Study: A New Frontier in Gastroesophageal Cancer Treatment - TipRanks

Aug 21, 2025
pulisher
Aug 21, 2025

AstraZeneca’s CHRONICLES COPD Study: A New Horizon in COPD Treatment - TipRanks

Aug 21, 2025
pulisher
Aug 21, 2025

AstraZeneca’s New CAR T-Cell Therapy Study: A Potential Game-Changer for Multiple Myeloma - TipRanks

Aug 21, 2025
pulisher
Aug 21, 2025

AstraZeneca’s New Study on Crohn’s Disease Treatment: Key Insights for Investors - TipRanks

Aug 21, 2025
pulisher
Aug 21, 2025

AstraZeneca’s Phase III COPD Study: A Potential Game-Changer in Respiratory Treatment - TipRanks

Aug 21, 2025
pulisher
Aug 21, 2025

Earnings call transcript: AstraZeneca’s Q2 2025 earnings exceed expectations - Investing.com

Aug 21, 2025
pulisher
Aug 20, 2025

AstraZeneca PLC ADR outperforms market on strong trading day - MarketWatch

Aug 20, 2025
pulisher
Aug 20, 2025

AstraZeneca’s Benralizumab Study Completes: A Potential Game-Changer for COPD Treatment - TipRanks

Aug 20, 2025
pulisher
Aug 20, 2025

AstraZeneca’s Phase 3 Study on Advanced Biliary Tract Cancer: A Potential Game-Changer? - TipRanks

Aug 20, 2025
pulisher
Aug 20, 2025

AstraZeneca’s Atuliflapon Study: A New Hope for Uncontrolled Asthma - TipRanks

Aug 20, 2025
pulisher
Aug 20, 2025

AstraZeneca’s Saruparib Study: A New Frontier in Cancer Treatment? - TipRanks

Aug 20, 2025
pulisher
Aug 20, 2025

AstraZeneca’s Phase III Study on Endometrial Cancer: A Potential Game Changer? - TipRanks

Aug 20, 2025
pulisher
Aug 20, 2025

AstraZeneca advances Wednesday, outperforms market - MarketWatch

Aug 20, 2025
pulisher
Aug 20, 2025

AstraZeneca’s New Asthma Treatment Study: What Investors Should Know - TipRanks

Aug 20, 2025
pulisher
Aug 19, 2025

Fitch Upgrades AstraZeneca on Profit Growth; Ratings Withdrawn for Commercial Reasons - MarketScreener

Aug 19, 2025
pulisher
Aug 19, 2025

AstraZeneca’s Benralizumab Study: A Step Forward in COPD Treatment - TipRanks

Aug 19, 2025
pulisher
Aug 19, 2025

Risk adjusted return profile for AstraZeneca PLC Depositary Receipt analyzed2025 Risk Factors & Intraday High Probability Alerts - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

AstraZeneca’s Promising Asthma Treatment: A Closer Look at the Atuliflapon Study - TipRanks

Aug 19, 2025
pulisher
Aug 19, 2025

AstraZeneca’s Phase I Study on Saruparib: A Potential Game-Changer in Cancer Treatment - TipRanks

Aug 19, 2025
pulisher
Aug 19, 2025

AstraZeneca’s New Study on Advanced Biliary Tract Cancer: A Potential Game Changer? - TipRanks

Aug 19, 2025
pulisher
Aug 18, 2025

AstraZeneca Receives Chinese Approval to Acquire FibroGen China - MarketScreener

Aug 18, 2025
pulisher
Aug 18, 2025

AstraZeneca’s Pediatric Hyperkalaemia Study: A Potential Market Game-Changer - MSN

Aug 18, 2025
pulisher
Aug 18, 2025

AstraZeneca CFO Aradhana Sarin sells 9,563 shares in London transaction - Investing.com

Aug 18, 2025
pulisher
Aug 17, 2025

AstraZeneca’s New Study on T-DXd Offers Hope for HER2-Positive Tumor Patients - MSN

Aug 17, 2025
pulisher
Aug 16, 2025

AstraZeneca (LSE:AZN) Launches FluMist Home For At-Home Influenza Vaccination - Yahoo Finance

Aug 16, 2025
pulisher
Aug 16, 2025

AstraZeneca’s LATIFY Study: A New Hope for NSCLC Treatment? - The Globe and Mail

Aug 16, 2025
pulisher
Aug 16, 2025

AstraZeneca’s CKD Registry Study: A Strategic Move in Nephrology - MSN

Aug 16, 2025
pulisher
Aug 16, 2025

AstraZeneca’s Promising Study on Durvalumab and Olaparib in Advanced Bladder Cancer - MSN

Aug 16, 2025
pulisher
Aug 16, 2025

AstraZeneca’s Phase I Study on Balcinrenone/Dapagliflozin: Key Insights for Investors - MSN

Aug 16, 2025
pulisher
Aug 16, 2025

Can swing trading help recover from AstraZeneca PLC Depositary Receipt lossesPortfolio Value Summary & AI Enhanced Market Trend Forecasts - Newser

Aug 16, 2025
pulisher
Aug 15, 2025

AstraZeneca’s Phase III Study: Baxdrostat and Dapagliflozin Combination for Heart Failure Prevention - MSN

Aug 15, 2025
pulisher
Aug 15, 2025

Wholesalers Want Final OK For $51M AstraZeneca Settlement - Law360

Aug 15, 2025
pulisher
Aug 15, 2025

AstraZeneca Launches At-Home Flu Vaccine Amid Industry DTC Push - insights.citeline.com

Aug 15, 2025
pulisher
Aug 15, 2025

AstraZeneca’s Innovative Approach in Cancer Treatment: A Study Update - TipRanks

Aug 15, 2025
pulisher
Aug 15, 2025

AstraZeneca’s Promising Phase 1 Study on AZD0486 for B-Cell Non-Hodgkin Lymphoma - TipRanks

Aug 15, 2025
pulisher
Aug 15, 2025

AstraZeneca’s New Study on Anifrolumab: What Investors Need to Know - TipRanks

Aug 15, 2025
Capitalizzazione:     |  Volume (24 ore):